Pharus Diagnostics的动态

Exciting developments are unfolding in the world of #ECMO! A recent study has shown that older adults bridged to lung transplants via ECMO have impressive long-term survival rates and allograft function up to 5 years post-transplant. This is a major step forward, as it expands the possibilities for older patients who might not have been considered for ECMO previously. This research emphasizes how ECMO can offer life-saving support for patients waiting for lung transplants, even for those who are older and in more critical conditions. At CBM Lifemotion, we’re inspired by these findings and dedicated to making ECMO even more accessible and impactful for patients worldwide. If you’re interested in learning more about these groundbreaking advancements, check out the article here: https://lnkd.in/er6PwJfC #ECMO #LungTransplant #Innovation #Healthcare

Sometimes, the biggest ideas come from the simplest thought: “I can help.” These are the words that drive Valentina Agudelo Vargas, turning the heartbreak of losing loved ones to late-stage diagnoses into a mission to save lives. Salva Health’s win represents more than innovation; it’s a lifeline for communities worldwide that need accessible, early cancer detection. Your success today means countless lives saved tomorrow. Here’s to the future where healthcare is accessible to all. In regions where early detection can be rare, Salva Health’s technology stands as a beacon of hope, bridging healthcare gaps for underserved populations. At Hyzync, we feel a deep connection to Salva Health’s purpose. Our Bionic platform shares a similar mission, using predictive, accessible cardiac care technology to prevent life-threatening conditions. Together, these innovations reflect a new era where technology helps erase healthcare disparities, giving hope and saving lives. Here’s to Salva Health, to Hyzync’s Bionic, and to a future where no one is left behind. #TechCrunchDisrupt #SalvaHealth #Hyzync #Bionic #HealthcareInnovation #EarlyDetection #SocialImpact

The Artera team is heading to #LUGPA, June 7-8 in Las Vegas! We look forward to engaging with urologists, practice administrators, advanced practice providers, and other key practice staff at LUGPA's Las Vegas Regional Meeting to discuss the evolving healthcare landscape and the role of AI in #precisionmedicine. Schedule your meeting with Artera's Peter Wood or Sydney Melnick to learn how we're helping shape the future of #cancertreatment decisions, starting with #prostatecancer. #ArteraOnTheGo

Weekend read alert! ?? At Qure4u, we're always innovating to help practices save resources and stay ahead of the competition. One of our latest features, Patient Navigator, reduces wait times and administrative burdens to foster an environment where both patients and staff thrive. Our vision for #PatientNavigator was simple: create an easy-to-implement solution that frees up healthcare teams while keeping patients in the know. The result? A ripple effect of improved patient flow and satisfaction across the entire organization. Curious about the impact? Discover how Affiliated Oncologists and Texas Oncology saw improvements within just a few hours! #TheQureUNeed Read the blog: https://lnkd.in/eDpy6E8u

Breaking barriers: Labplus enters clinics and hospitals! ???? Big news! We just made another #milestone - we're now in #hospitals and #clinics! ?? Radom Oncology Center (Radomskie Centrum Onkologii) and Radom Family Center are our pioneers. Why's this huge? 1?? First-ever #PrimaryCare facility offering Labplus 2?? Free pro interpretations for ALL patients 3?? Doctors saving 40% time (More care, less paperwork!) Imagine: You walk in for a routine #check, walk out with crystal-clear insights. No more "Dr. Google" nights! This isn't just about tech. It's about you - understanding your health as easily as checking your Instagram. We're turning "medical speak" into "human speak", one patient at a time. Read more ?? https://lnkd.in/drSUTRMe Next up? Your local clinic! ?? Stay healthy, stay informed! #HealthRevolution #Labplus #PatientPower #LabTestChecker #BloodTest P.S. #Doctors, ready to supercharge your practice? Let's talk! ??

We're thrilled to announce that we'll be once again a proud sponsor at the upcoming #NeuroNetPro Annual Summit in Dallas, Texas, this week; so, join our Account Director Rebecca Bartz, and our VP Science & Clinical Trials Annemie Ribbens from February 1st. At icometrix, we strongly believe in the inherent value that the private practice community sector brings, through superior patient access and cost-effective care.?Together, we can harness collective learnings on optimizing patient care, maximize value through AI adoption, share best practices, and pool resources to thrive in an increasingly sophisticated healthcare landscape. Our recent achievements in securing CPT codes (0865T & 0866T) underscore our commitment to advancing neuroimaging and enhancing patient care. This strategic positioning aligns seamlessly with the NeuroNet Pro Summit's focus on collaboration, innovation, and excellence. We're also?excited to announce our participation in the ARIA Bootcamp during the Summit, where we'll explore new frontiers in neuroimaging about a?topic close to our heart that could dramatically impact the care pathway of Alzheimer's disease patients today and tomorrow. ?? https://lnkd.in/ezsVWaRU Looking forward to connecting, collaborating, and elevating the future of neuroimaging at the NeuroNet Pro Annual Summit! ???? #NeuroNetProSummit #HealthcareInnovation #CPTcodes #NeuroImaging?

Forward Together…?We Did It Again "The renewed confidence from our investors reinforces that Ligence is on the right path: tackling the world’s biggest killer, cardiovascular disease, and advancing one of the key tests to diagnose it—cardiac ultrasound," says Ligence CEO Arnas Karu?as. Our heartfelt thanks go to lead investor Simpact Ventures, as well as the European Innovation Council and SMEs Executive Agency (EISMEA), Coinvest Capital, NGL, Lemonade Stand, and Rita Sakus for their belief in our mission and support for our team. Each investor brings invaluable insight, helping us move closer to a world where precise, efficient cardiac care is within reach. Finally, thank you to our cardiology community—clinicians, hospitals, and healthcare organizations—for trusting Ligence to enhance patient care and streamline diagnostic workflows. Together, we’re building a future of cardiac diagnostics that truly puts the heart in healthcare. If you want to know more about our investment round, look for a link in the comments bellow! Wojciech Majewski Viktorija Trimbel Justinas Pasys Siim Teller

Today is World Cancer Day and this year’s theme is “Close the Care Gap”. The reality today is that who you are and where you live could mean the difference between life and death. It isn’t fair and we must change this. There is hope. The first step is recognising inequity when we see it. Only then can we begin to challenge our own assumptions and biases, listen to the perspectives of people living with cancer and fight to close these gaps once and for all. The Alliance & Partnerships for Patient Innovation & Solutions (APPIS) platform, organized and funded by Novartis, was established in 2021 to bring patient communities and key stakeholders in the healthcare ecosystem together to prioritize action towards addressing barriers to access for patients in the region. https://lnkd.in/gEFs8MgM #WorldCancerDay #CancerAwareness #livingwithcancer #Equity #Novartis #reimaginemedicine #APPIS

On October 22, I’ll be taking the stage at HLTH Inc. in Las Vegas with Joaquin Duato, Johnson & Johnson Chairman & CEO. Joaquin and I have spoken before and I am looking forward to our fireside chat about bold ambitions for health care. We are both passionate about utilizing science and technology to solve some of our biggest health care challenges. Joaquin has even said science and technology will transform health care more in the next decade than the last century. We will discuss what leaders need to be thinking about now to realize the potential of the next wave of innovation. We will also discuss what we see possible for the future of cancer treatment. Curing cancer is considered an ultimate health moonshot, but getting treatments approved isn’t enough – we also need them to be widely adopted. We’ll share our thoughts for how we see treatments accelerated so they can get to patients faster.? Lastly, I’m going to ask about J&J’s future in cardio-health and how technology can help caregivers and health inequity. It is sure to be a fun panel - I hope you can join us! https://lnkd.in/eq9Q4M98 #HLTH24

??CardioSignal by Precordior announced the closing of $10 million in Series A funding. The investment will fund additional clinical validation of CardioSignal’s breakthrough technology and the expansion of its commercial efforts. ?? The company develops digital technologies and software-as-medical-devices to provide early detection of heart diseases, and provides the first and only technology to detect several major heart diseases with high accuracy using just one clinical modality without any specialized medical equipment. ?? Dr. Juuso Blomster, founder and CEO of CardioSignal, commented: “More than 20 million people die each year from cardiovascular diseases. This funding enables us to scale a detection and remote monitoring solution for primary care doctors and their patients. [...] We can support the shift in cardiovascular care from treating complications to earlier detection and prevention.” ?? Learn more here: https://lnkd.in/dXcjY9N7 ?? Follow Guided Solutions to receive the latest #MedTech news daily and subscribe to our weekly newsletter: https://lnkd.in/dPx-P6ZK #App #HeartDisease #Cardiology #FundingRound #Funding #GuidedSolutions